Select language:
On this page



    • Prevention of meningitis due to meningococci groups A, C and W135:
      • in mass immunisation campaigns in the event of an outbreak due to meningococcus A, C or W135
      • in travellers spending more than 1 month in hyperendemic areas

    Composition, forms, route of administration

    • Inactivated bacterial vaccine, polysaccharide
    • Powder for injection in multidose vial, to be dissolved with the entire vial of the diluent supplied by the manufacturer, for SC injection only

    Dosage and vaccination schedule

    • Child from 2 years and adult: 0.5 ml single dose

    Contra-indications, adverse effects, precautions

    • Do not administer to patients with history of an allergic reaction to a previous injection of meningococcal vaccine.
    • Vaccination should be postponed in the event of severe acute febrile illness; minor infections are not contra-indications.
    • May cause: mild local reaction, mild fever.
    • Do not mix with other vaccines in the same syringe (inactivation of vaccines).
    • If administered simultaneously with EPI vaccines, use different syringes and injection sites.
    • Pregnancy: no contra-indication
    • Breast-feeding: no contra-indication


    • Immunity develops 7 to 10 days after injection, and lasts for approximately 3 years.


    • Powder: between 2 °C and 8 °C.
    • Diluent: a cold chain is not required for storage. However, at least 12 hours before reconstitution of the vaccine, the diluent must be refrigerated between 2 °C and 8 °C so that the diluent and lyophilised powder are at the same temperature: a temperature difference during reconstitution may reduce vaccine efficacy. Do not freeze.
    • Reconstituted vaccine: between 2 °C and 8 °C, for 6 hours maximum.